-- (Moderated) The NEW Official Alizyme Thread: The Next Phase --

Willydoctor (Post 4352) I disagree with your comments about OXB, which appear to owe as much to the fact you think I have an interest in the Company as anything else; and are therefore seeking to damage my interests. Certainly, your comments run completely contrary to analyst reviews and trial data so far.

Note:

"TroVax is easily the best in class for cytotoxic T cell responses".

(Source: Alan Kingsman, CEO OXB, Webcast 5/9/2006)

.......................................

From the Webcast by OXB's CEO on 5/9/2006:




Slide 7: TroVax "Best in class"









Slide 14: "TroVax sales potential of $1 billion in renal and $3 billion in colorectal cancer".



Slide 15: Near Term Value Drivers include a "Commercial Partnership - Global Agreement" for TroVax.